Skip to main content
Erschienen in: International Journal of Hematology 4/2010

01.05.2010 | Case Report

Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?

verfasst von: Ping Chen, Bingzong Li, Wenzhuo Zhuang, Haiwen Huang, Hong Zhang, Jinxiang Fu

Erschienen in: International Journal of Hematology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

We encountered a 58-year-old female patient who developed hypercalcemia and multiple bone lesions. She complained of lumbodorsal pain, nausea and vomiting on admission. Radiographic examination revealed multiple osteolytic lesions. She was diagnosed diffuse large B cell lymphoma (BLBCL) by bone marrow examination and biopsy of cervical lymph node. She underwent eight cycles of chemotherapy and is now in the stable stage. Osteogenic potential of mesenchymal stem cells from bone marrow was found to be correlated with the expression of Dickkopf1 (DKK-1) in the bone marrow plasma and lymphoma cells before and after treatment. PTH-related protein (PTHrP) expression was detectable in the lymphoma cells and was elevated in the serum. The receptor activator of nuclear factor κB ligand expression was found to be elevated in the bone marrow plasma and mesenchymal stem cells. These findings suggest that factors affecting the differentiation of both osteoblasts and osteoclasts involved in the pathogenesis of hypercalcemia and bone lesions of lymphoma. This was similar to that of multiple myeloma in which bone lesions and hypercalcemia are frequently observed.
Literatur
1.
Zurück zum Zitat Rathmell AJ, Gospodarowicz MK, Sutcliffe SB, Clark RM. Localised lymphoma of bone: prognostic factors and treatment recommendations The Princess Margaret Hospital Lymphoma Group. Br J Cancer. 1992;66:603–6.PubMed Rathmell AJ, Gospodarowicz MK, Sutcliffe SB, Clark RM. Localised lymphoma of bone: prognostic factors and treatment recommendations The Princess Margaret Hospital Lymphoma Group. Br J Cancer. 1992;66:603–6.PubMed
2.
Zurück zum Zitat Horsman JM, Thomas J, Hough R, Hancock BW. Primary bone lymphoma: a retrospective analysis. Int J Oncol. 2006;28:1571–5.PubMed Horsman JM, Thomas J, Hough R, Hancock BW. Primary bone lymphoma: a retrospective analysis. Int J Oncol. 2006;28:1571–5.PubMed
3.
Zurück zum Zitat Fidias P, Spiro I, Sobczak ML, et al. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999;45:1213–8.CrossRefPubMed Fidias P, Spiro I, Sobczak ML, et al. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999;45:1213–8.CrossRefPubMed
4.
Zurück zum Zitat Hicks DG, Gokan T, O’Keefe RJ, et al. Primary lymphoma of bone. Correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer. 1995;75:973–80.CrossRefPubMed Hicks DG, Gokan T, O’Keefe RJ, et al. Primary lymphoma of bone. Correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer. 1995;75:973–80.CrossRefPubMed
6.
Zurück zum Zitat Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood. 1993;82:1383–94.PubMed Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood. 1993;82:1383–94.PubMed
7.
Zurück zum Zitat Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol. 2007;20:613–24.CrossRefPubMed Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol. 2007;20:613–24.CrossRefPubMed
8.
Zurück zum Zitat Li B, Shi M, Li J, et al. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev. 2007;16:921–30.CrossRefPubMed Li B, Shi M, Li J, et al. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev. 2007;16:921–30.CrossRefPubMed
9.
Zurück zum Zitat Matsuhashi Y, Tasaka T, Uehara E, et al. Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis. Leuk Lymphoma. 2004;45:397–400.CrossRefPubMed Matsuhashi Y, Tasaka T, Uehara E, et al. Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis. Leuk Lymphoma. 2004;45:397–400.CrossRefPubMed
10.
Zurück zum Zitat Takasaki H, Kanamori H, Takabayashi M, et al. Non-Hodgkin’s lymphoma presenting as multiple bone lesions and hypercalcemia. Am J Hematol. 2006;81:439–42.CrossRefPubMed Takasaki H, Kanamori H, Takabayashi M, et al. Non-Hodgkin’s lymphoma presenting as multiple bone lesions and hypercalcemia. Am J Hematol. 2006;81:439–42.CrossRefPubMed
11.
Zurück zum Zitat Evron E, Goland S, Klepfish A, et al. Primary multifocal lymphoma of bone presenting as hypercalcemic crisis: report of a rare manifestation of extranodal lymphoma. Leuk Lymphoma. 1999;34:197–200.PubMed Evron E, Goland S, Klepfish A, et al. Primary multifocal lymphoma of bone presenting as hypercalcemic crisis: report of a rare manifestation of extranodal lymphoma. Leuk Lymphoma. 1999;34:197–200.PubMed
12.
Zurück zum Zitat Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–9.CrossRefPubMed Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–9.CrossRefPubMed
13.
Zurück zum Zitat Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica. 2004;89:1118–23.PubMed Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica. 2004;89:1118–23.PubMed
14.
Zurück zum Zitat Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005;208:30–49.CrossRefPubMed Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005;208:30–49.CrossRefPubMed
15.
Zurück zum Zitat Shibata H, Abe M, Hiura K, et al. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-κB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Clin Cancer Res. 2005;11:6109–15.CrossRefPubMed Shibata H, Abe M, Hiura K, et al. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-κB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Clin Cancer Res. 2005;11:6109–15.CrossRefPubMed
16.
Zurück zum Zitat Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527–33.CrossRefPubMed Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527–33.CrossRefPubMed
17.
Zurück zum Zitat Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? Cancer Res. 2004;64:772–3.PubMed Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? Cancer Res. 2004;64:772–3.PubMed
18.
Zurück zum Zitat Giuliani N, Mangoni M, Rizzoli V. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol. 2009;37:879–86.CrossRefPubMed Giuliani N, Mangoni M, Rizzoli V. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol. 2009;37:879–86.CrossRefPubMed
19.
Zurück zum Zitat Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.CrossRefPubMed Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.CrossRefPubMed
20.
Zurück zum Zitat Stewart JP, Shaughnessy JD Jr. Role of osteoblast suppression in multiple myeloma. J Cell Biochem. 2006;98:1–13.CrossRefPubMed Stewart JP, Shaughnessy JD Jr. Role of osteoblast suppression in multiple myeloma. J Cell Biochem. 2006;98:1–13.CrossRefPubMed
21.
Zurück zum Zitat Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008;80:490–4.CrossRefPubMed Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008;80:490–4.CrossRefPubMed
22.
Zurück zum Zitat Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24:425–36.CrossRefPubMed Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24:425–36.CrossRefPubMed
23.
24.
Zurück zum Zitat Papapetrou PD, Bergi-Stamatelou M, Karga H, Thanou S. Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein. Eur J Endocrinol. 2003;148:351–5.CrossRefPubMed Papapetrou PD, Bergi-Stamatelou M, Karga H, Thanou S. Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein. Eur J Endocrinol. 2003;148:351–5.CrossRefPubMed
25.
Zurück zum Zitat Zeimer H, Firkin F, Grill V, et al. Assessment of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma. J Pathol. 2000;192:336–41.CrossRefPubMed Zeimer H, Firkin F, Grill V, et al. Assessment of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma. J Pathol. 2000;192:336–41.CrossRefPubMed
Metadaten
Titel
Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?
verfasst von
Ping Chen
Bingzong Li
Wenzhuo Zhuang
Haiwen Huang
Hong Zhang
Jinxiang Fu
Publikationsdatum
01.05.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0562-4

Weitere Artikel der Ausgabe 4/2010

International Journal of Hematology 4/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.